Table 3.

Demographic and descriptive data of AIH patients treated at our institution between 10/2011 and 05/2016.

Demographic data
Total number 10/2011-05/2016	n = 38
Age (median)	50 years
Male	n = 16 (42%)
Female	n = 22 (58%)
Cirrhosis	n = 4 (11%)
Ascites	n = 3 (8%)
Hepatic encephalopathy (grade 1)	n = 1 (3%)
MELD, median (range)	16 (6-23)
Other autoimmune disease	n = 21 (55%)
Simplified AIH score (available for n = 26)
Definite AIH (points ≥ 7)	n = 7 (27%)
Probable AIH (points > 6)	n = 8 (31%)
No AIH (points ≤ 5)	n = 11 (42%)
Liver histology (available for n = 28)
AIH typical	n = 8 (29%), interface hepatitis n = 3 (11%)
Inconclusive	n = 7 (25%)
Not performed	n = 10 (36%)
Immunosuppressive therapy
Prednisolone (mg), median (range)	60 mg (50-100 mg)
Prednisolone therapy duration (days), median (range)	180 days (60-1080 days)
Azathioprine (mg), median (range)	100 mg (50-200 mg)
Azathioprine start after weeks, median (range)	3 weeks (1-12 weeks)
Azathioprine intolerance	n = 11 (29%)
Conversion to MMF	n = 11 (29%)
Conversion to Everolimus	n = 2 (5%)
Outcome
Survival	n = 38 (100%)
Infection	n = 1 (3%)
Liver transplantation	n = 0 (0%)